Loading
A phase 2 trial of TAK-007 in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) is a phase 2 interventional study registered as NCT05020015 by Takeda, with 27 participants enrolled, started 2021-11-12 and due to reach its primary completion in 2024-06-16. Interventions recorded: TAK-007 and Chemotherapy Agents. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
27 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication
Sourcerange 1.7 to 20.3; Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication · Median was not estimable due to insufficient number of participants with events. · range 0.9 to 11.2 · Median was not estimable due to insufficient number of participants with events.
Sourcerange 0.85 to 1.02; Figures from the ClinicalTrials.gov results section (first posted 2025-08-12), not from a publication · range 0.95 to 9.00 · range 0.03 to 5.55 · range 2.83 to 8.77
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs)primary | Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells | 3 | 3 participants | - | - | link |
| Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 6 | 6 participants | ||||
| Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 10 | 10 participants | ||||
| Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 7 | 7 participants | ||||
| Overall Survival (OS) | Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells | 3 | 8.9 months | - | - | link |
| Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 6 | Median was not estimable due to insufficient number of participants with events. | ||||
| Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 10 | 8.4 months | ||||
| Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 7 | Median was not estimable due to insufficient number of participants with events. | ||||
| Progression-free Survival (PFS) Per Investigator | Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells | 3 | 0.95 months | - | - | link |
| Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 6 | 2.23 months | ||||
| Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 10 | 2 months | ||||
| Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells | 7 | 5.62 months |
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.